



## **Osiris Therapeutics to Present at the Canaccord Adams Diabetes and Obesity Conference**

**Columbia, Maryland – June 3, 2008** – Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas, announced today that management is scheduled to present at the Canaccord Adams Diabetes and Obesity Conference on Friday, June 6, 2008, at 1:00 p.m. PT in San Francisco, CA.

A live audio webcast of the presentation may be accessed through the Investors page of the Company's website at [www.Osiris.com](http://www.Osiris.com). An audio replay of the webcast will be available for 30 days following the conference.

### **About Osiris Therapeutics**

Osiris Therapeutics, Inc. is a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas. Osiris currently markets and sells OSTEOCEL for regenerating bone in orthopedic indications. PROCHYMAL is being evaluated in Phase III clinical trials for three indications, including acute and steroid refractory Graft versus Host Disease and also Crohn's disease, and is the only stem cell therapeutic currently designated by FDA as both an Orphan Drug and Fast Track product. Osiris has also partnered with Genzyme Corporation to develop PROCHYMAL as a medical countermeasure to nuclear terrorism and other radiological emergencies. PROCHYMAL is also being developed for the repair of heart tissue following a heart attack and for the protection of pancreatic islet cells in patients with type 1 diabetes. The Company's pipeline of internally developed biologic drug candidates under evaluation also includes CHONDROGEN for arthritis in the knee. Osiris is a fully integrated company, having developed capabilities in research, development, manufacturing, marketing and distribution of stem cell products. Osiris has developed an extensive intellectual property portfolio to protect the company's technology in the United States and a number of foreign countries including 47 U.S. and 253 foreign patents owned or licensed. More information can be found on the company's website, [www.Osiris.com](http://www.Osiris.com). (OSIR-G)

### **Forward-Looking Statements**

This press release may contain forward-looking statements. These forward-looking statements may generally be identified by the use of the words "may," "will," "expects," "anticipates," "believes," "estimates," and similar expressions, and involve a number of risks and uncertainties. For a variety of reasons, actual results may differ materially from those described in or contemplated by any such forward-looking statement. Consequently, the reader is cautioned to consider all forward-looking statements in light of the risks to which they are subject.

**For additional information, please contact:  
Erica Elchin, Osiris Therapeutics, Inc. at (443) 545-1834  
[OsirisPR@osiris.com](mailto:OsirisPR@osiris.com)**

**Media Contacts:  
Stacey Holifield/Andrew Law  
Schwartz Communications  
(781) 684-0770  
[Osiris@schwartz-pr.com](mailto:Osiris@schwartz-pr.com)**